Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Conn H. O. Ideal treatment of portal hypertension in 1985. Clin Gastroenterol. 1985 Jan;14(1):259–288. [PubMed] [Google Scholar]
- De Vita V. T., Jr Breast cancer therapy: exercising all our options. N Engl J Med. 1989 Feb 23;320(8):527–529. doi: 10.1056/NEJM198902233200812. [DOI] [PubMed] [Google Scholar]
- Freiman J. A., Chalmers T. C., Smith H., Jr, Kuebler R. R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978 Sep 28;299(13):690–694. doi: 10.1056/NEJM197809282991304. [DOI] [PubMed] [Google Scholar]
- Karjalainen S., Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ. 1989 Oct 28;299(6707):1069–1072. doi: 10.1136/bmj.299.6707.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mackillop W. J., Palmer M. J., O'Sullivan B., Ward G. K., Steele R., Dotsikas G. Clinical trials in cancer: the role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment. Br J Cancer. 1989 Mar;59(3):388–395. doi: 10.1038/bjc.1989.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Taylor K. M., Margolese R. G., Soskolne C. L. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med. 1984 May 24;310(21):1363–1367. doi: 10.1056/NEJM198405243102106. [DOI] [PubMed] [Google Scholar]